Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 2,347 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects

NCT01818011
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 Initial fit for purpose tablets, GSK1322322 over granulated tablets, GSK1322322 intended commercial tablets, Placebo tablets, 13C-GSK1322322 stable isotope powder, GSK1322322 for injection, Placebo injection
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

NCT01746784
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
N6022, Normal saline
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
17
States / cities
Birmingham, Alabama • Anchorage, Alaska • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism

NCT00612352
View directory record Official record
Conditions
Alcoholism
Interventions
Ethanol High Dose, Ethanol Low Dose, and Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 30 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

NCT03824392
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo
Biological
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Northridge, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Not applicable Interventional

Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients

NCT02470299
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Ketorolac, Placebo
Drug · Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Heritability of Opioid Effects: A Twin Study

NCT00672438
View directory record Official record
Conditions
Pain
Interventions
Alfentanil, Saline placebo infusion
Drug · Other
Lead sponsor
Martin Angst
Other
Eligibility
18 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Phase 1Phase 2 Interventional

N-acetylcysteine in Intra-amniotic Infection/Inflammation

NCT00397735
View directory record Official record
Conditions
Labor, Premature, Preterm Premature Rupture of the Membranes, Infection, Inflammation, Chorioamnionitis
Interventions
amniocentesis, N-acetylcysteine or placebo
Procedure · Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
2
States / cities
New Haven, Connecticut • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Phase 2 Interventional Results available

Intravenous Allopurinol in Heart Failure

NCT00181155
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Intravenous Norepinephrine for Orthostatic Hypotension

NCT01285908
View directory record Official record
Conditions
Orthostatic Hypertension
Interventions
Intravenous Norepinephrine Infusion
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

NCT03197935
View directory record Official record
Conditions
Triple-negative Breast Cancer
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Placebo, Nab-paclitaxel, Doxorubicin, Cyclophosphamide, Filgrastim, Pegfilgrastim
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
12
States / cities
Palo Alto, California • Norwalk, Connecticut • Carrollton, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients

NCT00738621
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant, Dexamethasone, Ondansetron, Aprepitant, Dexamethasone, Placebo
Drug
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 17, 2026, 3:25 PM EDT
Terminated Phase 2 Interventional Results available

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)

NCT02357147
View directory record Official record
Conditions
Mesothelioma, Malignant
Interventions
Placebo, Amatuximab, Pemetrexed, Cisplatin
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
La Jolla, California • Newark, Delaware • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients

NCT04605978
View directory record Official record
Conditions
Primary Sjögren's Syndrome
Interventions
S95011 concentrate for solution for infusion, Placebo concentrate for solution for infusion
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Lakewood, Colorado • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 17, 2026, 3:25 PM EDT
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Phase 1 Interventional Results available

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

NCT02624778
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3002813, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Delray Beach, Florida • Orlando, Florida • The Villages, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

NCT06445075
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Apitegromab, Placebo, Tirzepatide
Drug
Lead sponsor
Scholar Rock, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
7
States / cities
Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

NCT04129164
View directory record Official record
Conditions
Sjögren's Syndrome
Interventions
VIB4920, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Fullerton, California • Upland, California • Lawrenceville, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 17, 2026, 3:25 PM EDT
Not yet recruiting Phase 3 Interventional

NICU Antibiotics and Outcomes (NANO) Follow-up Study

NCT05977400
View directory record Official record
Conditions
Premature Birth, Antibiotics, Neurodevelopment
Interventions
Ampicillin, Gentamicin, Placebo
Drug
Lead sponsor
Sharp HealthCare
Other
Eligibility
23 Weeks to 30 Weeks
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
14
States / cities
San Diego, California • New Haven, Connecticut • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

NCT03277261
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ublituximab, Teriflunomide, Oral Placebo, IV Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Carlsbad, California • Long Beach, California • Pasadena, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

NCT03310021
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet alfa, Apixaban, Rivaroxaban, Edoxaban, Placebo
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

NCT00055536
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
18
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Immediate Post-Operative Anesthesia With Either Lidocaine or Bupivacaine

NCT06293807
View directory record Official record
Conditions
Periodontal Diseases
Interventions
Xylocaine 2 % with 1:100,000 epinephrine, Bupivicaine 0.5% with 1:200,000 epinephrine, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 17, 2026, 3:25 PM EDT
Terminated Phase 3 Interventional Results available

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

NCT02231164
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
docetaxel, placebo, nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Highland, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 17, 2026, 3:25 PM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia

NCT02164981
View directory record Official record
Conditions
Schizophrenia
Interventions
sodium nitroprusside, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Glen Oaks, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 17, 2026, 3:25 PM EDT